We are live on
!
Find out more
ACG
Anchorage Capital Group Portfolio holdings
AUM
$436M
1-Year Est. Return
38.51%
This Fund
S&P 500
This Quarter
Est. Return
-9.38%
1 Year Est. Return
-38.51%
3 Year Est. Return
-18.86%
5 Year Est. Return
-55.07%
10 Year Est. Return
+90.94%
AUM
$780M
AUM Growth
-$341M
(-30%)
Cap. Flow
-$334M
Cap. Flow
% of AUM
-42.88%
Top 10 Holdings %
Top 10 Hldgs %
92.45%
Holding
20
New
–
Increased
1
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ginkgo Bioworks
DNA
|
+$1.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$2.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.09% |
| 2 | Communication Services | 19.67% |
| 3 | Technology | 19.51% |
| 4 | Consumer Discretionary | 6.04% |
Similar funds
VDBMI
VIM
TECP
NF
REMPR
SCP
SWG
MWC
Anchorage Capital Group's Q4 2022 Portfolio in Review
As of Q4 2022, Anchorage Capital Group held 20 positions worth $780M, down 30% from $1.12B the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Anchorage Capital Group withdrew a net $334M in Q4 2022, closing 1 position. Its most notable exit was Zymergen Inc. Common Stock, an estimated $2.11M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Anchorage Capital Group added an estimated $1.6M to Ginkgo Bioworks.
- Anchorage Capital Group added most to Ginkgo Bioworks in Q4 2022, an estimated $1.6M increase.
- Anchorage Capital Group fully exited Zymergen Inc. Common Stock in Q4 2022, selling an estimated $2.11M.
- Anchorage Capital Group's ten largest holdings make up 92% of its $780M portfolio in Q4 2022.
- Anchorage Capital Group opened 0 new positions and closed 1 in Q4 2022.
- Anchorage Capital Group's portfolio value fell 30% quarter-over-quarter to $780M.
Based on Anchorage Capital Group's 13F filing for Q4 2022, filed 14 Feb 2023.